Sunshine Biopharma (SBFM) Net Income towards Common Stockholders (2011 - 2026)

Sunshine Biopharma's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 5.43% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 4.35% YoY) and the FY2025 annual result came in at -$6.0 million, down 16.39% from the prior year.
• Net Income towards Common Stockholders was -$1.2 million for Q1 2026 at Sunshine Biopharma, up from -$2.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $295951.0 in Q3 2025 and bottomed at -$23.5 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of -$1.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 3624.47% — and 2025, when it jumped 124.71%.
• Sunshine Biopharma's Net Income towards Common Stockholders stood at -$23.5 million in 2022, then soared by 94.85% to -$1.2 million in 2023, then slumped by 78.07% to -$2.2 million in 2024, then grew by 0.8% to -$2.1 million in 2025, then soared by 41.9% to -$1.2 million in 2026.
• Business Quant data shows SBFM's Net Income towards Common Stockholders at -$1.2 million in Q1 2026, -$2.1 million in Q4 2025, and $295951.0 in Q3 2025.